<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">Fourth, in addition to negotiating with China to increase supply, the United States must consider increasing the domestic manufacture of active pharmaceutical ingredients.
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> Since factories closed in China, and India shut down exports of medications, we have been under the threat of shortages in multiple medications.
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib12" ref-type="bibr">
  <sup>12</sup>
 </xref> There have since been some signs of improvement, but the situation is fluid, and may worsen. This pandemic reminds us of the importance of having backup manufacturing within the United States, supported by taxpayer funds if needed.
</p>
